)

Belite Bio (BLTE) investor relations material
Belite Bio H.C. Wainwright 27th Annual Global Investment Conference summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Clinical development updates
DRAGON trial for Stargardt disease completed last patient visit; top-line data expected by end of Q4 2024, with NDA submission planned for H1 2026.
Tinlarebant showed prevention and slowed growth of atrophic lesions in phase II, with nearly 50% reduction compared to controls.
Safety profile remains excellent, with withdrawal rate due to ocular adverse events under 4%.
PHOENIX trial in geographic atrophy (GA) fully enrolled; top-line data expected Q3 2027.
DRAGON 2 trial fully enrolled by end of 2024; top-line data expected two years later.
Regulatory and market strategy
FDA granted breakthrough designation for Tinlarebant based on interim analysis; full approval to be sought in US and other major markets.
Regulatory strategy includes broad label submissions in US, Europe, Japan, UK, Switzerland, and Australia.
Japanese approval requires DRAGON 2 trial data due to Sakigake designation and PMDA requirements.
Market focus will be on Stargardt first, leveraging orphan indication pricing and specialist networks.
Market opportunity and competition
Estimated US Stargardt prevalence is 47,000–59,000, with potential market penetration of over 20,000 patients.
Tinlarebant expected to be effective in both adolescent and adult populations, with no age restriction anticipated.
Nanoscope's gene therapy seen as complementary, targeting late-stage vision loss, while Tinlarebant aims to prevent progression.
Tinlarebant's oral administration could make it a first-line therapy for GA if efficacy matches complement inhibitors.
Next Belite Bio earnings date

Next Belite Bio earnings date

The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
)
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
)
I can't remember the last time an app had such a positive impact on my investment process.
)
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
)
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
)
I can't remember the last time an app had such a positive impact on my investment process.
)
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
)
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
)
)
)
)
Frequently asked questions
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Explore our global coverage